Patisiran sodiumProduct ingredient for Patisiran
- Name
- Patisiran sodium
- Drug Entry
- Patisiran
Parisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis 4. It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. Onpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.
- Accession Number
- DBSALT002783
- Structure
- Synonyms
- Not Available
- UNII
- WO0YM16LKG
- CAS Number
- 1386913-72-9
- External Links
- Not Available
- Predicted Properties
- Not Available